Does Cigna Cover Dupixent?

How Cigna Classifies Dupixent on Its Formulary

Cigna places Dupixent on its specialty pharmacy tier across most commercial, Cigna Healthcare, and Medicare Advantage plans. This means the drug is covered, but with the highest level of cost-sharing and administrative requirements. Specialty-tier biologics carry separate copay or coinsurance structures that differ from standard formulary tiers.

On most Cigna commercial plans, Dupixent falls under the "Specialty" or "Tier 5" designation. Members typically face coinsurance of 25% to 33% rather than a flat copay, though some plans cap annual specialty drug out-of-pocket costs. The drug's wholesale acquisition cost (WAC) sits near $3,819 per month for the standard adult dose of 300 mg every two weeks, placing the annual list price above $45,000.

Cigna Medicare Advantage and Cigna Supplemental plans may apply different formulary rules. Medicare Part D specialty tiers generally require coinsurance of 25% to 33% during the initial coverage phase, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (fully effective in 2025 and continuing through 2026) significantly limits total exposure for Medicare beneficiaries. This cap applies to all Part D covered drugs, including Dupixent, once the plan approves the prescription [1].

Cigna updates its formulary quarterly, and specific plan documents (the "Summary of Benefits" or "Evidence of Coverage") supersede any general guidance. Your HR department or Cigna member services line (number on the back of your card) can confirm exact tier placement for your plan year.

Prior Authorization: What Cigna Requires Before Approving Dupixent

Nearly every Cigna plan requires prior authorization (PA) before covering Dupixent. The PA process confirms that the patient meets clinical criteria, that cheaper alternatives have been tried, and that the prescribing physician has documented medical necessity.

Cigna's published clinical coverage policies outline specific requirements that vary by indication. For moderate-to-severe atopic dermatitis in adults, the standard criteria include a confirmed diagnosis by a dermatologist or allergist, documented failure or intolerance of at least one medium-to-high potency topical corticosteroid used for a minimum of four weeks, and trial of at least one systemic immunosuppressant such as methotrexate, cyclosporine, or mycophenolate [2]. The European Academy of Dermatology and Venereology (EADV) and American Academy of Dermatology (AAD) guidelines both support dupilumab as a first-line biologic for moderate-to-severe atopic dermatitis after topical therapy failure, and Cigna's criteria broadly align with these recommendations [3].

For asthma, Cigna generally requires documentation of the eosinophilic phenotype (blood eosinophils ≥150 cells/μL) or oral corticosteroid dependence, plus failure of at least one high-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab reduced severe asthma exacerbations by 47.7% in patients with baseline eosinophils ≥150 cells/μL compared to placebo over 52 weeks [4].

For chronic rhinosinusitis with nasal polyps (CRSwNP), prior authorization typically demands failure of intranasal corticosteroids and at least one prior sinus surgery or documented ineligibility for surgery. The SINUS-24 trial (N=276) showed dupilumab reduced nasal polyp scores by 1.89 points vs. placebo at week 24, with significant improvement in nasal congestion and smell loss [5].

Your prescriber's office handles the PA submission. The process typically takes 5 to 15 business days for a standard review, though urgent requests can be expedited to 24 to 72 hours.

Step Therapy Rules and How to Manage Them

Step therapy is the most common barrier Cigna members face when seeking Dupixent coverage. This "fail first" protocol requires patients to try and fail less expensive treatments before the insurer approves a biologic.

For atopic dermatitis, most Cigna plans mandate at least two steps before approving Dupixent. Step one requires a trial of topical therapies (corticosteroids, calcineurin inhibitors like tacrolimus or pimecrolimus). Step two requires trial and failure or intolerance of at least one conventional systemic agent. Some plans also require documentation that phototherapy was considered. A 2023 analysis published in the Journal of the American Academy of Dermatology found that step therapy requirements for biologics delayed effective treatment by a median of 6.5 months in moderate-to-severe atopic dermatitis patients [6].

There are clinical scenarios where step therapy can be bypassed. If a patient has documented contraindications to systemic immunosuppressants (for example, renal insufficiency that rules out cyclosporine, or hepatotoxicity risk with methotrexate), the prescriber can request a step therapy exception. Cigna's own clinical policy allows exceptions when "the required step therapy drug is contraindicated or has caused an adverse reaction" or when "the patient is stable on the requested drug and switching would be medically inappropriate."

To strengthen an exception request, the prescribing physician should include: specific prior medications with dates, doses, and documented outcomes; photographs of affected skin (for dermatology indications); validated scoring tools such as the Eczema Area and Severity Index (EASI) or Investigator Global Assessment (IGA); and relevant lab results showing contraindications to step-therapy agents.

What You Will Actually Pay Out of Pocket

The real cost of Dupixent with Cigna insurance depends on three variables: your plan's specialty tier coinsurance rate, your annual out-of-pocket maximum, and whether you qualify for copay assistance.

Without any copay assistance, a Cigna commercial plan member facing 30% coinsurance on a $3,819 monthly drug would owe roughly $1,146 per month, or $13,750 annually, until hitting the plan's out-of-pocket maximum. Most Cigna commercial plans cap out-of-pocket spending between $4,000 and $8,550 for individual coverage (the 2026 ACA maximum for individual in-network out-of-pocket costs is $9,450) [7]. Once you hit that cap, the plan covers 100% for the rest of the year.

Sanofi and Regeneron's Dupixent MyWay copay assistance program covers most or all out-of-pocket costs for commercially insured patients. Eligible patients can pay as little as $0 per fill, with the program covering up to $13,000 per year in copay and coinsurance costs. The program is available to patients with commercial insurance (including Cigna commercial plans) but explicitly excludes patients on Medicare, Medicaid, TRICARE, or other government-funded insurance [8].

For Cigna Medicare Advantage members, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap provides meaningful relief. Before this cap took full effect, Medicare patients on Dupixent could face annual out-of-pocket costs exceeding $10,000 in the coverage gap. The Dupixent MyWay program offers separate support for Medicare patients, including a patient assistance program for those who meet income eligibility requirements.

Cigna also requires Dupixent to be dispensed through its preferred specialty pharmacy network, most commonly Accredo (Cigna's own specialty pharmacy subsidiary). Using an out-of-network specialty pharmacy may result in higher cost-sharing or outright denial. Confirm your plan's specialty pharmacy requirements before your first fill to avoid unexpected charges.

How to Appeal a Cigna Dupixent Denial

If Cigna denies your Dupixent prior authorization, you have the right to appeal. Denial is not uncommon for specialty biologics, and a structured appeal significantly improves the chance of reversal.

Cigna's internal appeal process allows two levels of review before a case can be escalated to an independent external review organization. The first-level appeal must be filed within 180 days of the denial notice. Industry-wide data from the AMA's 2023 Prior Authorization Physician Survey indicate that approximately 80% of physicians report that PA denials are sometimes, often, or always overturned on appeal, suggesting that initial denials frequently do not reflect final medical determination [9].

A successful appeal letter should include a detailed letter of medical necessity from the prescribing physician that references Cigna's own clinical coverage policy criteria, documentation of all prior treatments with specific dates, doses, duration, and reasons for discontinuation, relevant clinical scoring (EASI score for atopic dermatitis, ACQ-5 for asthma, nasal polyp score for CRSwNP), supporting peer-reviewed literature or guideline citations that specifically support dupilumab for the patient's condition and clinical profile, and any relevant photographs or test results.

If both internal appeal levels are denied, federal law (the ACA and ERISA for employer-sponsored plans) guarantees the right to an external review by an independent third party. External reviewers overturn insurer denials in a meaningful percentage of cases. The Kaiser Family Foundation has documented that external review processes provide an important safeguard for patients, particularly for high-cost specialty medications [10].

Your state insurance commissioner's office can also assist with complaints if you believe the denial violates state parity laws or coverage mandates.

FDA-Approved Indications That Cigna May Cover

Dupixent (dupilumab) has received FDA approval for six distinct conditions as of 2026, and Cigna's coverage policies address each with specific clinical criteria.

Moderate-to-severe atopic dermatitis remains the most common indication. The FDA first approved dupilumab for this use in adults in March 2017 and has since expanded the label to include patients as young as 6 months old. The key SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that 36% to 38% of adults receiving dupilumab 300 mg every two weeks achieved clear or almost clear skin (IGA 0/1) at week 16, compared to 8% to 10% on placebo [2].

For moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependence, dupilumab was approved in October 2018 for patients aged 12 and older, later expanded to ages 6 and up. The LIBERTY ASTHMA VENTURE trial showed a 70.1% reduction in oral corticosteroid dose while maintaining asthma control [4].

CRSwNP gained approval in June 2019. Eosinophilic esophagitis (EoE) approval followed in May 2022, making dupilumab the first FDA-approved treatment for EoE in patients aged 12 and older weighing at least 40 kg. Prurigo nodularis received approval in September 2022. Most recently, the FDA approved dupilumab for COPD with an eosinophilic phenotype (blood eosinophils ≥300 cells/μL) in September 2024, based on the BOREAS and NOTUS trials showing 30% and 34% reductions in moderate-to-severe exacerbations, respectively [11].

Each indication carries separate Cigna PA criteria. A prescriber seeking coverage for an off-label use will face a higher denial rate and may need to pursue an appeal with strong supporting literature.

Cigna vs. Other Major Insurers: How Coverage Compares

Cigna's Dupixent coverage requirements are broadly similar to those of UnitedHealthcare, Aetna, and Blue Cross Blue Shield plans, though specific step therapy requirements and formulary tier placements vary.

All major commercial insurers require prior authorization for Dupixent. Step therapy requirements are nearly universal, with most demanding failure of at least one topical and one systemic therapy for atopic dermatitis. Where plans differ most is in the number of required step therapy failures and the specific agents accepted. Some UnitedHealthcare plans, for example, accept a documented trial of JAK inhibitors (such as upadacitinib or abrocitinib) as an alternative step before Dupixent, while certain Cigna plans do not yet list oral JAK inhibitors as acceptable step therapy agents [12].

A 2022 study in JAMA Dermatology analyzed commercial insurance claims data and found that among patients prescribed dupilumab for atopic dermatitis, 37% experienced a PA-related delay of 30 days or more, and 12% abandoned the prescription entirely due to insurance barriers [6]. These numbers were consistent across Cigna, UnitedHealthcare, and Aetna claims.

Specialty pharmacy requirements also differ. Cigna routes most Dupixent prescriptions through Accredo. UnitedHealthcare uses Optum Specialty Pharmacy. Aetna (a CVS Health company) directs prescriptions through CVS Specialty. These routing requirements generally do not affect the patient's copay, but they do affect which pharmacy your prescriber sends the prescription to and may influence delivery timelines.

One area where Cigna distinguishes itself: the Cigna Patient Assurance Program, available in some plan designs, caps specialty drug copays at a set amount per prescription. If your employer has selected a plan with this feature, your Dupixent copay could be significantly lower than the standard coinsurance calculation would suggest.

Tips for Getting Dupixent Approved Through Cigna the First Time

Preparation before submitting the prior authorization request is the single most effective way to avoid denial and delay.

First, verify your specific Cigna plan's clinical coverage policy for dupilumab before your prescriber submits the PA. These policies are available on Cigna's provider portal or by calling the number on your member ID card. Knowing the exact criteria allows the prescriber to proactively address each requirement in the PA submission.

Second, compile documentation thoroughly. The PA submission should include a complete medication history with dates and outcomes, validated clinical scores (EASI, IGA, BSA for atopic dermatitis; FEV1, ACQ, blood eosinophil counts for asthma), relevant lab work showing contraindications to step therapy agents, clinical photographs if applicable, and a letter of medical necessity that explicitly maps the patient's history to Cigna's published criteria.

Third, use Dupixent MyWay concurrently. The manufacturer's support program assigns a case manager who can help track the PA, provide bridge supply if there are delays, and assist with appeal documentation if needed. Enrollment is free and available at dupixentmyway.com.

Fourth, set expectations on timeline. Standard PA reviews take 5 to 15 business days. If clinical urgency exists (severe flare, oral corticosteroid dependence, hospitalization risk), request an expedited or urgent review, which Cigna must process within 72 hours for commercial plans and 24 hours for Medicare Advantage urgent requests per CMS regulations [13].

For the COPD indication specifically, given its more recent approval, some Cigna plan formularies may not yet have updated clinical policies. If you encounter a denial citing "not FDA-approved" or "experimental," provide the FDA approval letter dated September 2024 and the published BOREAS trial results as part of the appeal [11].